Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Profit After Tax
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024
Compare Profit and Loss Results of Astrazeneca Phar
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
1,716.00
2,519.00
-803.00
-31.88%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
1,716.00
2,519.00
-803.00
-31.88%
Expenditure (Ex Depriciation)
Stock Adjustments
-332.00
-33.00
-299.00
-906.06%
Raw Materials Consumed
1,295.00
917.00
378.00
41.22%
Power & Fuel Cost
5.00
3.00
2.00
66.67%
Employee Cost
257.00
367.00
-110.00
-29.97%
Operating Expenses
18.00
58.00
-40.00
-68.97%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
93.00
122.00
-29.00
-23.77%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
13.00
42.00
-29.00
-69.05%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
1,462.00
1,615.00
-153.00
-9.47%
Operating Profit (PBDIT) excl Other Income
253.00
904.00
-651.00
-72.01%
Other Income
40.00
187.00
-147.00
-78.61%
Operating Profit (PBDIT)
294.00
1,092.00
-798.00
-73.08%
Interest
1.00
9.00
-8.00
-88.89%
Profit before Depriciation and Tax
293.00
1,082.00
-789.00
-72.92%
Depreciation
39.00
57.00
-18.00
-31.58%
Profit Before Taxation & Exceptional Items
253.00
1,024.00
-771.00
-75.29%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
156.00
975.00
-819.00
-84.00%
Provision for Tax
40.00
253.00
-213.00
-84.19%
Profit After Tax
115.00
722.00
-607.00
-84.07%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
578.00
2,435.00
-1,857.00
-76.26%
Profit Available for appropriations
693.00
3,158.00
-2,465.00
-78.06%
Appropriations
693.00
3,158.00
-2,465.00
-78.06%
Equity Dividend (%)
1600%
750%
850.00
Earnings Per Share
46.3
157.92
-111.62
-70.68%
Profit And Loss - Net Sales
Net Sales 1,716.29 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 253.97 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Profit And Loss - Interest
Interest 1.46 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Profit And Loss - Profit After Tax
Profit After Tax 115.74 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024






